Another Humira Biosimilar Debuts In India
This article was originally published in Scrip
Executive Summary
A second biosimilar version of AbbVie's blockbuster biologic, Humira (adalimumab), has made its debut in India, with Torrent Pharma following Zydus Cadila onto the domestic market with its version.